首页> 美国卫生研究院文献>The Journal of Neuroscience >Stimulation of the Calcitonin Gene-Related Peptide Enhancer by Mitogen-Activated Protein Kinases and Repression by an Antimigraine Drug in Trigeminal Ganglia Neurons
【2h】

Stimulation of the Calcitonin Gene-Related Peptide Enhancer by Mitogen-Activated Protein Kinases and Repression by an Antimigraine Drug in Trigeminal Ganglia Neurons

机译:丝裂素激活的蛋白激酶对降钙素基因相关肽增强剂的刺激和三叉神经节神经元中抗偏头痛药物的抑制作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Calcitonin gene-related peptide (CGRP) is involved in the underlying pathophysiology of all vascular headaches, including migraines. Elevated levels of CGRP during migraine are restored to normal coincident with headache relief after treatment with the antimigraine drug sumatriptan. We have used primary cultures of trigeminal neurons under conditions simulating migraine pathology and therapy to study the mechanisms controlling the CGRP promoter. Using reporter genes in transient transfection assays, we demonstrate that an 18 bp enhancer containing a helix–loop–helix element is both necessary and sufficient for full promoter activity. NGF treatment and cotransfection with an upstream activator of the extracellular signal-regulated MAP kinases (MAPKs) activated the enhancer. Treatment with sumatriptan repressed NGF- and MAPK-stimulated CGRP promoter activity. Repression was also observed using a synthetic MAPK-responsive reporter gene. Sumatriptan regulation of CGRP gene expression did not couple to a Gi/Gopathway, but rather caused a prolonged increase in intracellular calcium. The importance of the prolonged calcium signal in repression of MAPK activity was demonstrated by using the ionophore ionomycin to mimic sumatriptan action. We propose that activation of MAPK pathways may increase CGRP gene expression during migraine, and that sumatriptan can diametrically oppose that activation via a prolonged elevation of intracellular calcium.
机译:降钙素基因相关肽(CGRP)参与所有血管性头痛(包括偏头痛)的潜在病理生理。用抗偏头痛药物舒马曲坦治疗后,偏头痛中的CGRP水平恢复正常,并伴有头痛缓解。我们已经在模拟偏头痛病理学和治疗的条件下使用了三叉神经元的原代培养物来研究控制CGRP启动子的机制。使用瞬时转染测定中的报告基因,我们证明了含有螺旋-环-螺旋元件的18 bp增强子对于启动子的完整活性是必要和充分的。 NGF治疗和细胞外信号调节MAP激酶(MAPKs)上游激活剂的共转染激活了增强子。舒马曲坦治疗抑制了NGF和MAPK刺激的CGRP启动子活性。还使用合成的MAPK反应报告基因观察到了抑制作用。舒马曲坦对CGRP基因表达的调节未与Gi / Gopathway偶联,而是导致细胞内钙的长期升高。通过使用离子载体ionomycin模拟舒马曲坦作用证明了延长的钙信号在抑制MAPK活性中的重要性。我们提出,MAPK途径的激活可能会增加偏头痛过程中CGRP基因的表达,而舒马曲坦可以通过延长细胞内钙的浓度完全反对这种激活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号